Logo

SBFMW

Sunshine Biopharma, Inc.

SBFMW

Sunshine Biopharma, Inc. • NASDAQ
$0.25 ▼ -3.66% (-0.01)
Market Cap $8.02 M
52w High $0.30
52w Low $0.20
Dividend Yield 0%
P/E -0.11
Volume 1.21K
Outstanding Shares 30.82M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $9.41M ▲ $5.478M ▲ $-1.771M ▼ -18.818% ▼ $-7.8 ▼ $-1.907M ▼
Q1-2025 $8.901M ▼ $4.026M ▼ $-1.18M ▲ -13.257% ▲ $-0.44 ▲ $-1.155M ▲
Q4-2024 $9.595M ▲ $5.131M ▲ $-2.158M ▼ -22.491% ▼ $-0.84 ▲ $-2.213M ▼
Q3-2024 $8.435M ▼ $3.973M ▲ $-1.198M ▼ -14.203% ▼ $-0.94 ▲ $-918K ▼
Q2-2024 $9.303M $3.574M $-494K -5.31% $-9.94 $-787K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $9.306M ▼ $31.487M ▼ $7.288M ▲ $24.199M ▼
Q2-2025 $10.305M ▲ $31.965M ▲ $6.28M ▼ $25.685M ▲
Q1-2025 $8.195M ▼ $29.187M ▼ $6.485M ▼ $22.702M ▼
Q4-2024 $9.687M ▼ $30.56M ▲ $7.06M ▲ $23.501M ▼
Q3-2024 $12.207M $30.057M $5.018M $25.039M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-1.771M ▼ $-1.273M ▲ $-491.778K ▼ $3.61M ▲ $2.181M ▲ $-1.824M ▲
Q1-2025 $-1.18M ▲ $-1.714M ▲ $-176.024K ▲ $338.137K ▼ $-1.562M ▲ $-1.926M ▲
Q4-2024 $-2.158M ▼ $-3.407M ▼ $-531.535K ▲ $2.054M ▲ $-2.52M ▼ $-3.847M ▼
Q3-2024 $-1.198M ▼ $-1.361M ▲ $-578.368K ▼ $1.866M ▲ $698.91K ▲ $-1.878M ▲
Q2-2024 $-494.3K $-4.578M $-542.208K $-28.583K $-5.926M $-5.15M

Five-Year Company Overview

Income Statement

Income Statement The company’s income statement shows it is still at a very early commercial stage. Revenue has only recently started to appear and remains very small, though gross profit is positive, which suggests basic product economics can work. Operating and net results hover around a small loss, implying the business is not yet covering its overhead and R&D costs from operations. The extremely volatile earnings per share history likely reflects changes in share count or reverse splits more than shifts in the underlying business performance, so the headline EPS figures are somewhat misleading on their own.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small asset base and a modest cash position, but no financial debt. Equity essentially funds the whole operation, which limits interest burden but makes the company reliant on equity capital and internal cash generation. The thin capital base means the company has limited cushion if cash burn accelerates or R&D spending rises. Overall, it looks lean but also financially fragile, with little room for major setbacks without new funding.

Cash Flow

Cash Flow Cash flow from operations has been modestly negative for several years, showing that the core business and R&D still consume cash rather than generate it. Free cash flow mirrors this pattern, as there is little to no spending on physical assets, so the main outflows are operating costs and development expenses. The current burn rate looks small in absolute terms, but so is the cash balance, so duration of the cash runway is an important uncertainty. Sustained progress will likely depend on either improved cash generation from the generics arm or additional capital raises.

Competitive Edge

Competitive Edge Competitively, Sunshine Biopharma is trying to stand out through a hybrid model: a commercial generics and biosimilars platform (Nora Pharma) that supports a more speculative oncology and antiviral pipeline. The generics and biosimilars business operates in a crowded, price-sensitive market, but a broad and growing product portfolio, including a biosimilar to a well-known oncology support drug, can help build presence and relationships with prescribers and payers. On the innovative side, the focus on multidrug-resistant cancers and coronavirus protease inhibitors targets areas of genuine medical need and scientific interest, which can be differentiating if the programs succeed. However, the company is still small relative to established pharma players, and faces intense competition, regulatory complexity, and substantial clinical risk, so its moat is promising but not yet proven.

Innovation and R&D

Innovation and R&D Innovation and R&D are at the heart of the story. The company is pursuing three main proprietary programs: a chemotherapy candidate aimed at drug-resistant cancers, an mRNA-based anticancer approach, and an antiviral targeting a key coronavirus enzyme. All three sit at early, largely preclinical stages, where scientific upside can be significant but the likelihood and timing of success are highly uncertain. The use of the generics business to fund these projects helps reduce reliance on constant external financing, but progress will depend on successfully moving at least one of these candidates into and through clinical trials, as well as maintaining strong intellectual property around these technologies.

Summary

Overall, Sunshine Biopharma appears to be a very small, development-focused biopharma company using a commercial generics and biosimilars arm to support a more ambitious oncology and antiviral pipeline. Historically reported financials show minimal revenue, small but persistent losses, and a limited cash base, suggesting the business is still in a formative phase and sensitive to funding conditions. Strategically, the dual-engine model and focus on multidrug resistance, mRNA oncology, and coronavirus targets offer a clear narrative and potential differentiation. At the same time, the company faces the usual early-stage biotech challenges: execution risk in scaling the generics business, heavy scientific and regulatory hurdles for its pipeline, and a thin balance sheet that leaves little room for delays or setbacks. Outcomes are likely to be highly dependent on future clinical milestones and the company’s ability to translate its strategy into sustained cash generation.